Prevalence of CYP2C19*2 carriers in Saudi ischemic stroke patients and the suitability of using genotyping to guide antiplatelet therapy in a university hospital setup.
Abdullah M Al-RubaishFahad A Al-MuhannaAbdullah M AlshehriAbdulla A AlsulaimanMajed M AlabdulaliFahad AlkhamisAbdulallh S AlamriRudaynah A AlaliMohammed S AkhtarCyril CyrusDaniel M F ClaassensFolkert W AsselbergsAmein K Al-AliPublished in: Drug metabolism and personalized therapy (2021)
This study shows the suitability of using genotyping to guide antiplatelet therapy in ischemic stroke patients in a clinical setting.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- end stage renal disease
- newly diagnosed
- high throughput
- ejection fraction
- genome wide
- coronary artery disease
- atrial fibrillation
- risk factors
- peritoneal dialysis
- oxidative stress
- patient reported outcomes
- saudi arabia
- subarachnoid hemorrhage